Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 11—November 2024
Research Letter

Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia

Alex-Mikael Barkoff1, Tamara Kastrin1, Katja Seme, Marta Grgič Vitek, Jussi Mertsola, and Qiushui HeComments to Author 
Author affiliation: National Reference Laboratory for Pertussis and Diphtheria, Institute of Biomedicine, University of Turku, Turku, Finland (A.-M. Barkoff, J. Mertsola, Q. He); InFLAMES Research Flagship Center, University of Turku, Turku (A.-M. Barkoff, J. Mertsola, Q. He); National Laboratory of Health, Environment and Food Department for Public Health Microbiology, Ljubljana, Slovenia (T. Kastrin); Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana (K. Seme); Communicable Diseases Centre, National Institute of Public Health, Ljubljana (M. Grgič Vitek)

Main Article

Table

Pertussis vaccines assessed in a study of prevalence of pertactin-deficient Bordetella pertussis isolates, Slovenia*

Year Primary vaccines with PRN
 Primary vaccines without PRN
 Booster vaccines with PRN
Infanrix† Zagreb dTP‡ Infanrix/Hib§ Infanrix/IPV+Hib¶ Pentaxim# Hexacima** Boostrix†† Adacel‡‡
1999
 X
 X
2000
X
 X
2001
 X
X
2002
X
2003
X
 X
2004
X
2005
X
2006
X
X
2007
X
X
2008
X
X
2009
X
X
X
2010
X
X
X
2011
X
X
2012
X
X
X
2013
X
X
2014
X
X
2015
X
X
2016
X
X
X
2017
X
X
2018
X
X
2019
X
X
2020
X
 X
X
 X
2021
X
X
2022
X
X
2023 X X

*X indicates year vaccine was in use. Vaccination coverage for the primary series has been 90% higher since 2002; booster dose given at 8 years of age was introduced in 2009, and its coverage has ranged from 90.0% to 96.9% since its introduction. DT, diphtheria toxoid; FHA, filamentous hemagglutinin; FIM, fimbriae; HBsAg, hepatitis B virus surface antigen; Hib, Hemophilus influenzae type B; IPV, inactivated polio virus; PRN, pertactin; PT, pertussis toxin; TT, tetanus toxoid. †GlaxoSmithKline (https://www.gsk.com); formulation PT-FHA-PRN-DT-TT. ‡Institute of Immunology and Tumor Genetics (https://www.info.hazu.hr); pertussis whole-cell vaccine. §GlaxoSmithKline; formulation PT-FHA-PRN-DT-TT-Hib. ¶GlaxoSmithKline; formulation PT-FHA-PRN-DT-TT-IPV-Hib. #Sanofi Pasteur (https://www.sanofi.us); formulation PT-FHA-DT-TT-IPV-Hib. **Sanofi Pasteur; formulation PT-FHA-DT-TT-IPV-Hib-HBsAg. ††GlaxoSmithKline; formulation PT-FHA-PRN-DT-TT. ‡‡Sanofi Pasteur; formulation PT-FHA-PRN-FIM2-FIM3-DT-TT.

Main Article

1These first authors contributed equally to this article.

Page created: September 30, 2024
Page updated: October 23, 2024
Page reviewed: October 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external